arrow
H

Havva Yeşil Çınkır

gaziantep university
H指数:12
被引数:516

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501)

切除后胆道癌的辅助化疗方案:国家性、比较性、观察性研究(TOG/GI-SAFRADJU-2501)

2026-08-150
OAAI
Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group

BRAF阴性转移性黑色素瘤患者在接受纳武利尤单抗治疗后进展的实体世界治疗结果:土耳其肿瘤学小组进行的多中心队列研究

2026-07-040
OA
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

CDK4/6抑制剂在胚系BRCA1/2突变、激素受体阳性、HER2阴性转移性乳腺癌中的真实世界疗效:土耳其肿瘤学组(TOG)研究

2026-06-170
OA
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

比较固定剂量与体重基础剂量纳武利尤单抗治疗非小细胞肺癌患者的疗效

2026-05-080
OAAI
Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

基线维生素D状态及接受纳武利尤单抗治疗的晚期非小细胞肺癌患者的临床结局

2026-04-140
OAAI
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

转移性髓样甲状腺癌中的酪氨酸激酶抑制剂治疗:土耳其肿瘤学组的真实世界数据

2026-03-190
OA
The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

接受免疫疗法治疗的晚期肺癌患者中,早期肺部免疫预后指数变化的预后意义

2026-02-210
OAAI
Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival

慢性肾病与地诺单抗在骨转移性疾病中的应用:一项关于严重低钙血症、骨骼事件和生存情况的多中心土耳其队列研究

2025-11-210
OAAI
Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

晚期子宫平滑肌肉瘤中多柔比星–异环磷酰胺与吉西他滨–多西他赛方案的真实世界比较:一项多中心回顾性研究

2025-11-170
OAAI
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

卡博替尼与舒尼替尼在晚期非透明细胞肾细胞癌中的真实世界比较:土耳其肿瘤学集团的多中心研究

2025-09-010
PRE
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (vol 24, 16, 2024)
2024-01-230
OAAI
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
2024-01-022
OAAI